Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema

Michelle Lerman, Julia A. Gaebler, Sunday Hoy, Jessica Izhakoff, Laura Gullett, Timothy Niecko, Pinar Karaca Mandic, Thomas O'Donnell, Stanley G. Rockson

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Objective: Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients. Methods: This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs. Results: After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P =.001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P <.001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. FLX was also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85% lower total costs ($1153 vs $7449; P =.008) driven by 93% lower inpatient costs ($297 vs $4215; P =.002), 84% lower outpatient hospital costs ($368 vs $2347; P =.020), and 85% lower other outpatient-related costs ($353 vs $2313; P =.023). Compared with APCDs, FLX was associated with 53% lower total costs ($3973 vs $8436; P =.032) because of lower outpatient costs and lower rates of cellulitis (22.4% vs 44.9% of patients; P =.02). Conclusions: This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema.

LanguageEnglish (US)
Pages571-580
Number of pages10
JournalJournal of vascular surgery
Volume69
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Insurance Benefits
Economics
Costs and Cost Analysis
Equipment and Supplies
Outpatients
Hospital Costs
Inpatients
Venous Insufficiency
Cellulitis
Lymphedema
Occupational Therapy
Touch
Complementary Therapies
Insurance
Intelligence
Hospitalization

Keywords

  • Cellulitis
  • Flexitouch
  • Medical resource utilization
  • Phlebolymphedema
  • Pneumatic compression device
  • Venous ulcer

PubMed: MeSH publication types

  • Journal Article

Cite this

Lerman, M., Gaebler, J. A., Hoy, S., Izhakoff, J., Gullett, L., Niecko, T., ... Rockson, S. G. (2019). Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. Journal of vascular surgery, 69(2), 571-580. https://doi.org/10.1016/j.jvs.2018.04.028

Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. / Lerman, Michelle; Gaebler, Julia A.; Hoy, Sunday; Izhakoff, Jessica; Gullett, Laura; Niecko, Timothy; Karaca Mandic, Pinar; O'Donnell, Thomas; Rockson, Stanley G.

In: Journal of vascular surgery, Vol. 69, No. 2, 01.02.2019, p. 571-580.

Research output: Contribution to journalArticle

Lerman, M, Gaebler, JA, Hoy, S, Izhakoff, J, Gullett, L, Niecko, T, Karaca Mandic, P, O'Donnell, T & Rockson, SG 2019, 'Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema', Journal of vascular surgery, vol. 69, no. 2, pp. 571-580. https://doi.org/10.1016/j.jvs.2018.04.028
Lerman, Michelle ; Gaebler, Julia A. ; Hoy, Sunday ; Izhakoff, Jessica ; Gullett, Laura ; Niecko, Timothy ; Karaca Mandic, Pinar ; O'Donnell, Thomas ; Rockson, Stanley G. / Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. In: Journal of vascular surgery. 2019 ; Vol. 69, No. 2. pp. 571-580.
@article{e44a5c6b290040f79fd1cc7fe5787c6c,
title = "Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema",
abstract = "Objective: Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients. Methods: This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs. Results: After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69{\%} lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P =.001). This was driven by 59{\%} fewer mean annual hospitalizations (0.13 vs 0.32; P <.001) corresponding to 82{\%} lower inpatient costs and 55{\%} lower outpatient hospital costs. FLX was also associated with 52{\%} lower outpatient physical therapy and occupational therapy costs and 56{\%} lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85{\%} lower total costs ($1153 vs $7449; P =.008) driven by 93{\%} lower inpatient costs ($297 vs $4215; P =.002), 84{\%} lower outpatient hospital costs ($368 vs $2347; P =.020), and 85{\%} lower other outpatient-related costs ($353 vs $2313; P =.023). Compared with APCDs, FLX was associated with 53{\%} lower total costs ($3973 vs $8436; P =.032) because of lower outpatient costs and lower rates of cellulitis (22.4{\%} vs 44.9{\%} of patients; P =.02). Conclusions: This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema.",
keywords = "Cellulitis, Flexitouch, Medical resource utilization, Phlebolymphedema, Pneumatic compression device, Venous ulcer",
author = "Michelle Lerman and Gaebler, {Julia A.} and Sunday Hoy and Jessica Izhakoff and Laura Gullett and Timothy Niecko and {Karaca Mandic}, Pinar and Thomas O'Donnell and Rockson, {Stanley G.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jvs.2018.04.028",
language = "English (US)",
volume = "69",
pages = "571--580",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema

AU - Lerman, Michelle

AU - Gaebler, Julia A.

AU - Hoy, Sunday

AU - Izhakoff, Jessica

AU - Gullett, Laura

AU - Niecko, Timothy

AU - Karaca Mandic, Pinar

AU - O'Donnell, Thomas

AU - Rockson, Stanley G.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objective: Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients. Methods: This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs. Results: After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P =.001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P <.001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. FLX was also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85% lower total costs ($1153 vs $7449; P =.008) driven by 93% lower inpatient costs ($297 vs $4215; P =.002), 84% lower outpatient hospital costs ($368 vs $2347; P =.020), and 85% lower other outpatient-related costs ($353 vs $2313; P =.023). Compared with APCDs, FLX was associated with 53% lower total costs ($3973 vs $8436; P =.032) because of lower outpatient costs and lower rates of cellulitis (22.4% vs 44.9% of patients; P =.02). Conclusions: This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema.

AB - Objective: Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients. Methods: This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs. Results: After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P =.001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P <.001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. FLX was also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85% lower total costs ($1153 vs $7449; P =.008) driven by 93% lower inpatient costs ($297 vs $4215; P =.002), 84% lower outpatient hospital costs ($368 vs $2347; P =.020), and 85% lower other outpatient-related costs ($353 vs $2313; P =.023). Compared with APCDs, FLX was associated with 53% lower total costs ($3973 vs $8436; P =.032) because of lower outpatient costs and lower rates of cellulitis (22.4% vs 44.9% of patients; P =.02). Conclusions: This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema.

KW - Cellulitis

KW - Flexitouch

KW - Medical resource utilization

KW - Phlebolymphedema

KW - Pneumatic compression device

KW - Venous ulcer

UR - http://www.scopus.com/inward/record.url?scp=85048466342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048466342&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2018.04.028

DO - 10.1016/j.jvs.2018.04.028

M3 - Article

VL - 69

SP - 571

EP - 580

JO - Journal of Vascular Surgery

T2 - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 2

ER -